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Abstract
Background: Colorectal cancer (CRC) remains one of the major cancer types and cancer related death worldwide. Sensitive,
non-invasive biomarkers that can facilitate disease detection, staging and prediction of therapeutic outcome are highly
desirable to improve survival rate and help to determine optimized treatment for CRC. The small non-coding RNAs,
microRNAs (miRNAs), have recently been identified as critical regulators for various diseases including cancer and may
represent a novel class of cancer biomarkers. The purpose of this study was to identify and validate circulating microRNAs in
human plasma for use as such biomarkers in colon cancer.
Methodology/Principal Findings: By using quantitative reverse transcription-polymerase chain reaction, we found that
circulating miR-141 was significantly associated with stage IV colon cancer in a cohort of 102 plasma samples. Receiver
operating characteristic (ROC) analysis was used to evaluate the sensitivity and specificity of candidate plasma microRNA
markers. We observed that combination of miR-141 and carcinoembryonic antigen (CEA), a widely used marker for CRC,
further improved the accuracy of detection. These findings were validated in an independent cohort of 156 plasma samples
collected at Tianjin, China. Furthermore, our analysis showed that high levels of plasma miR-141 predicted poor survival in
both cohorts and that miR-141 was an independent prognostic factor for advanced colon cancer.
Conclusions/Significance: We propose that plasma miR-141 may represent a novel biomarker that complements CEA in
detecting colon cancer with distant metastasis and that high levels of miR-141 in plasma were associated with poor
prognosis.
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Introduction
Colorectal cancer (CRC) is a worldwide health problem with
655,000 deaths per year [1]. In the United States, CRC is the third
most common cancer type and the second most common cause of
cancer-related death [2], with an estimated 51,370 deaths in 2010
according to the National Cancer Institute. In China, CRC
remains the fifth most common cancer type and the fourth most
common cause of cancer-related death [3]. Despite early screening
and development of new chemotherapeutic strategies, CRC
survival rates during the past 20 years have not substantially
improved. Moreover, the incidence of CRC is increasing rapidly
in recent years in China [4]. Novel biomarkers that are of clinical
value are thus in urgent need to improve compliance rates.
Carcinoembryonic antigen (CEA) has been used as a serum
marker of CRC, although its sensitivity has varied in different
studies [5,6]. Recently, a family of small regulatory RNAs,
microRNAs, has emerged as possible plasma markers for human
diseases including cancers due to their relative stability in the
circulation [7].
MicroRNAs are small non-coding RNAs (18–22 nt in length)
that regulate the expression of target genes by interfering with
transcription or inhibiting translation [8]. Studies have demon-
strated that microRNAs play a crucial role in almost all cellular
biological processes including metabolism, survival, differentiation
and apoptosis. Deregulation of specific microRNAs contributes to
a variety of diseases, most notably the development and
progression of cancer, including CRC. Specifically, microRNA
expression profiling in CRC showed that a number of micro-
RNAs, including miR-21, miR-20a and miR155 were upregulated
in tumor tissues and that higher miR-21 was associated with poor
therapeutic outcome [9,10]. The potential of circulating miRNAs
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h 17  in plasma as cancer biomarkers has also been evaluated in a few
studies. For CRC, a recent study reported that miR-92 levels were
significantly higher in plasma samples from patients than in
healthy controls and can be a potential marker for CRC detection
[11]. A study of plasma samples from prostate cancer patients
reported that plasma miR-141 levels can be used to screen for
metastatic prostate cancer with high sensitivity [12].
In this proof-of-principle study to identify potential biomarkers
for CRC, we examined whether selected candidate microRNAs
could serve as non-invasive, blood-based markers for CRC by
analyzing the relative levels of three microRNAs (miR-21, miR-92,
and miR-141) in a cohort of 102 plasma samples from healthy
individuals and CRC patients obtained from TexGen, a
collaboration of Texas Medical Center Institutions. Our initial
data indicated that among these three microRNAs, plasma miR-
141 levels were significantly elevated in the plasma of colon cancer
patients with Stage IV disease and could readily discriminate
distant metastasis cases from normal controls and patients with
other stages. Combination of miR-141 with CEA was comple-
mentary and could further increase the detection accuracy of
distant metastasis in colon cancer. These findings were validated in
an independent cohort of 156 plasma samples obtained from
Tianjin, China. Our further analyses provided supporting
evidence that plasma miR-141 was a potential prognostic factor
that predicted for poor survival in colon cancer patients.
Interestingly, unlike in plasma, miR-141 was not differentially
expressed in tumor tissues between Stage IV and Stage I–II colon
cancer patients or between tumor tissues and adjacent non-tumor
tissues in Stage IV patients, suggesting that elevation of plasma
miR-141 in Stage IV patients might be derived from other
systemic responses such as inflammatory reactions in these
patients.
Materials and Methods
Ethics statement
Both plasma- and tissue-based studies were approved by the
Institutional Review Board (IRB) at the MD Anderson Cancer
Center and by the Ethics Committee at the Tianjin Medical
University Cancer Institute and Hospital. All participants gave
written consent of their information to be stored in the hospital
database and used for research.
Clinical samples
Two independent sets of plasma samples were used. A total of
102 plasma samples from age- and gender- matched healthy
individuals and CRC patients (Stage I–IV) were obtained from
TexGen between 2002 and 2008, a collaboration of Texas
Medical Center institutions that provides biological samples as well
as epidemiological and clinical data (TexGen samples, See Table
S1). An independent cohort of 156 plasma samples from age- and
gender- matched healthy donors and colon cancer patients (Stage
I–IV) were obtained at the Tianjin Medical University Cancer
Institute and Hospital, Tianjin, China (TCH samples) between
2007 and 2009 (See Table S2). Pathologic classification of disease
in all patients was performed following the International Union
Against Cancer (UICC) and American Joint Committee on
Cancer (AJCC) TNM staging system for colon cancer established
in 2003. Blood samples were collected from all patients before
operation and therapy. CEA levels of both TexGen and TCH
plasma samples were measured by standard enzyme immunoassay
as part of routine clinical tests and were acquired from the clinical
database at each institute. Follow-up data of all the recruited colon
cancer patients from both TexGen and TCH were acquired and
survival time was calculated from date of diagnosis to the date of
death or last follow-up in June, 2010. All patients recruited to this
study had not received chemotherapy or radiotherapy prior to the
blood draws. The demographic information of the two sets of
samples is summarized in the supplemental material.
For the tissue-based analysis tumor tissues from 21 colon cancer
patients with distant metastatic disease (Stage IV) and 24 colon
cancer patients with non-metastatic disease (Stage I and II) were
collected between 2007 and 2009 by Tianjin Medical University
Cancer Institute and Hospital from the same patients whose
plasma samples were used.
RNA isolation and quantitative RT-PCR
Small RNA was enriched from all plasma samples using the
mirVana PARIS RNA isolation kit (Ambion, Austin, TX). Briefly,
250 mL of plasma was thawed on ice and centrifuged at
14,000 rpm for 10 minutes to remove cell debris and other
cellular organelles. Next, 150 mL of supernatant was lysed with an
equal volume of 2x denaturing solution. For normalization of
sample-to-sample variation during the RNA isolation procedures,
25 fmol of synthetic C. elegans miRNA cel-miR-39 was added to
each denatured sample. Small RNAs were then enriched and
purified following manufacturer’s protocol, with the exception that
the enriched small RNAs were eluted in 45 mL of preheated
nuclease-free water. Standard TRIZOL method (Invitrogen) was
used to isolate total RNA from colon tissues.
For microRNA based RT-PCR assays, 2.5 mL of enriched small
RNAs from plasma samples were reverse transcribed using the
TaqMan MicroRNA Reverse Transciption Kit (Applied Biosys-
tems, San Diego, CA) according to manufacturer’s instructions in
a total reaction volume of 7.5 mL. A 1:20 dilution of RT products
was used as template for the PCR stage. PCR reaction was
performed in triplicates using TaqMan 2x Universal PCR Master
Mix with conditions as described previously [13]. No-template
controls for both RT step and PCR step were included to ensure
target specific amplification. The 7900 Sequence Detection
System 2.3 (Applied Biosystems) software defaults were used to
compute the relative change in RNA expression by the 2
2DDCt
method with 95% confidence intervals. Assays for the TexGen
specimens were performed at MD Anderson and assays for the
TCH specimens were performed at Tianjin Medical University
Cancer Institute and Hospital.
MicroRNA profiling
MicroRNA microarray profiling was performed with RNA
isolated from the Maryland cohort using the Ohio State
microRNA microarray version 2.0 as previously described [9].
Microarray data (including raw and processed data) have been
deposited in National Center for Biotechnology Information’s
(NCBI’s) Gene Expression Omnibus (NCBIGEO GSE7828).
Statistical analysis
The statistical significance was determined by using the
Wilcoxon signed-rank tests between groups. Receiver operating
characteristic (ROC) curves were generated to assess the
diagnostic accuracy of each parameter, and the sensitivity and
specificity of the optimum cut-off point were defined as those
values that maximized the area under the ROC curve (AUC). The
relative levels of microRNA were quantified using the 2
2DDCt
method, and the data were analyzed as the log10 of the relative
quantity of the target microRNA. The statistical analysis was
performed with the use of software packages SPSS version 16.0
(WPSS Ltd., Surrey, United Kingdom) and graphs were generated
using Graphpad Prism 5.0 (Graphpad Software Inc, California).
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tion between plasma miR-141 expression and CRC stages. All
statistical tests were two-sided, and a P value of 0.05 was
considered significant. The correlation between overall survival
and plasma miR-141 was analyzed using Kaplan-Meier method
and Log-rank test. Cox proportional-hazards regression analysis
was used to evaluate whether plasma miR-141 was an indepen-
dent prognostic factor for colon cancer.
Results
Plasma miR-141 levels are correlated with clinical stages
in colon cancer
Three microRNAs (miR-21, miR-92 and miR-141) were
selected in our studies to examine their potential to serve as
biomarkers for colon cancer. These candidate miRNAs were
selected because 1) miR-21 has been found to be upregulated in
CRC tumor tissues [9,10,14]; 2) miR-92 has recently been
reported to be a plasma marker for colon cancer [11]; and 3) miR-
141 has been shown to be a potential plasma marker for metastatic
prostate cancer [12]. Quantitative RT-PCR based microRNA
assays on these three miRNAs were performed. We first examined
the correlation between these three miRNAs and colon cancer
clinical stages. Stage I and Stage II cases were grouped together in
our analysis because only limited Stage I cases were available.
Heat-map analysis showed that the miR-141 levels clustered
according to different stages (Figure 1, A). Spearman correlation
analysis showed that the plasma miR-141 levels were highly
correlated with colon cancer stages (r=0.605, P=1.17610
28). In
contrast, miR-21 and miR-92 were less correlated with clinical
stages (Figure 1, A).
We next analyzed whether these candidate microRNAs could
serve as circulating colon cancer markers by comparing their
plasma levels between cancer patients and normal controls.
Surprisingly, unlike the previous report that upregulation of plasma
miR-92 was a colon cancer biomarker, the Wilcoxon two-sample
test showed that among these three microRNAs, plasma miR-92
was significantly decreased in the TexGen cohort of colon cancer
patients (p=0.03) (Figure 1, D). However, the decrease in plasma
miR-92 was only observed in Stage I–II and Stage III and the level
Figure 1. Plasma miR-141, miR-21 and miR-92 levels in healthy controls and colon cancer patients. (A) Each row corresponds to a plasma
miRNA and each column corresponds to each sample. Expression levels for each miRNA are normalized across the samples and shaded in colors such
that red denotes high expression and green denotes low expression. Spearman correlation shows that miR-141 is highly correlated with stages
(r=0.605, P=1.17610
28). (B–G) The relative levels of selected plasma microRNAs were normalized to spike-in control cel-miR-39 and shown as the
log10 of the relative quantity (RQ). The Wilcoxon two-sample tests were performed to examine the difference of selected plasma microRNAs between
normal controls and colon cancer patients (B–D), or between normal controls and/or colon cancer patients with different clinical stages (E–G).
doi:10.1371/journal.pone.0017745.g001
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colon cancer (Figure 1, G). Plasma levels of miR-21 and miR-141
did not show significant difference between controls and cancer
patients (Figure 1, B & C). After stratification of the cancer patients
according to their clinical stages, plasma miR-141 was significantly
upregulated in Stage IV colon cancer (Figure 1, E). To a much less
extent, plasma miR-21 was also shown to be elevated in Stage IV
coloncancer(Figure1,F).Basedontheseobservations, wesoughtto
focus on miR-141 for further characterization.
High plasma miR-141 levels are associated with Stage IV
colon cancer and complement with CEA in diagnosis
The above results demonstrated that among the three selected
microRNAs, miR-141 was significantly correlated with colon
cancer stages. The detailed Wilcoxon two-sample test showed that
the plasma miR-141 was significantly elevated in Stage IV cases
when compared with Stage I–II, Stage III and Stage I–III
combined. The ROC curve was plotted to identify a cut-off value
that could distinguish stage IV colon cancer from other groups.
ROC curve analysis showed that at the optimal cut-off, plasma
miR-141 had a 90.9% sensitivity and a 77.1% specificity in
separating Stage IV cases from Stage I–II cases with an AUC of
0.861 (Figure 2, B), a 77.1% sensitivity and a 89.7% specificity in
separating Stage IV and Stage III cases with an AUC of 0.803
(Figure 2, C), and a 77.1% sensitivity and a 89.7% specificity in
separating the Stage IV and combined Stage I–III cases with an
AUC of 0.836 (Figure 2, D). Our analysis also revealed that in this
cohort, plasma miR-141 was significantly elevated in Stage III
patients compared with early stage patients (p=0.025) (Figure 2,
A). These results suggest that circulating miR-141 might be a novel
biomarker for metastatic colon cancer.
Because the blood CEA test is widely used marker for CRC
patients, we sought to compare the performance of miR-141 with
CEA as a biomarker. We examined whether a combination of
miR-141 and CEA was more sensitive than either marker when
used individually. Our analysis showed that they were indeed
complementary. When the specificity was set at 100%, miR-141
identified seven Stage IV colon cancer that were missed by CEA
alone and CEA identified four Stage IV metastatic colon cancer
cases that were missed by miR-141 alone (Figure 3).
Validation of plasma miR-141 as a colon cancer marker in
an independent population
Results from the above studies provided evidence that high
levels of circulating miR-141 could be a potential biomarker that
complements CEA for metastatic colon cancer. To further validate
the potential utility of miR-141 in the clinical management of
colon cancer, we performed a validation study with an
independent set of plasma samples (TCH samples) (See Table
S2 for demographic information of TCH cases). The measure-
ments were made independently following the same experimental
procedures used for the TexGen samples.
The results validated that the plasma miR-141 level was
significantly higher in Stage IV patients than in normal controls,
Figure 2. Higher plasma miR-141 is significantly associated with Stage IV colon cancer in the training set. (A) Small RNA was isolated
from plasma samples and miR-141 was measured by quantitative RT-PCR assays. The Wilcoxon two-sample test was performed to evaluate
differences of miR-141 levels between the Stage III and Stage I–II groups. ROC analysis was performed to determine the sensitivity and specificity with
the value of AUC in the right panel. The Wilcoxon two-sample tests between (B) Stage IV and Stage I–II, (C) Stage IV and Sage III, and (D) Stage IV and
Stage I–III groups were performed to evaluate the association of plasma miR-141 with Stage IV disease status.
doi:10.1371/journal.pone.0017745.g002
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ROC curves showed that a cut-off for plasma miR-141 could be
determined with a 66.7% sensitivity and a 80.8% specificity for
separating the Stage IV cases from the Stage I–II cases
(AUC=0.756) (Figure 4, B), a 66.7% sensitivity and a 89.7%
specificity for separating from Stage III cases (AUC=0.779)
(Figure 4, C), and a 66.7% sensitivity and a 84.0% specificity for
separating from Stage 1–III cases (AUC=0.764) (Figure 4, D).
Unlike in TexGen plasma samples, we however failed to detect a
significant difference in miR-141 levels between Stage III and
Stage I–II cases (not shown), suggesting that higher plasma miR-
141 is more associated with distant and less with lymph-node
metastasis in colon cancer.
We also evaluated the CEA data in the TCH dataset. Similar
to what was shown in the TexGen samples, combination of miR-
141 and CEA identified additional metastatic cases that were
otherwise missed by either marker used alone (Figure 4, E). This
finding validated that the combination of these two biomarkers
was a more effective approach for detecting Stage IV CRC
patients.
Plasma miR-141 is correlated with poor survival in colon
cancer
To further evaluate whether plasma miR-141 levels can predict
prognosis, we next performed a survival analysis on TexGen and
TCH cases. Kaplan-Meier survival curves showed that higher
expression of plasma miR-141 was significantly correlated with
poor survival both in TexGen (P=0.004, log-rank test) and
Tianjin (P=0.002, log-rank test) cohorts (Figure S1, A and B).
Univariate Cox regression analysis demonstrated that plasma
miR-141 was a significant prognostic indicator of the colon cancer
in TexGen (HR=3.80, 95%CI=1.46291) and Tianjin cases
(HR=4.83, 95%CI=2.06211.35), respectively (Table 1). To
avoid any potential bias between the TexGen cohort and Tianjin
cohort, we performed the univariate and multivariate survival
analyses for all cases. The multivariate Cox proportional hazard
regression analysis showed that plasma miR-141was an indepen-
dent prognostic marker in colon cancer patients when we merged
the samples from both centers (HR=2.40, 95%CI=1.1824.86)
(Table 1).
MiR-141 is not differentially expressed in colon cancer
tissues
We sought to determine whether the elevated miR-141 in
plasma from Stage IV CRC patients reflected differential
expression in the tumor tissues from different disease stages. We
first compared miR-141 levels in tumor tissues between Stage I–II
and Stage IV in the TCH cohort, which surprisingly showed that
miR-141 was not upregulated in Stage IV cases (p=0.495)
(Figure 5, A). We next analyzed our previously described
microRNA microarray profiling data (GEO, GSE7828). Our
analysis also confirmed that the miR-141 level was not significantly
higher in tumor tissues than in adjacent normal tissues in stage IV
patients, as well as in patients of other stages (Figure 5, B).
Discussion
In this study, we took a focused approach and examined three
candidate microRNAs for their potential value as plasma
biomarkers for colon cancer. Results from the Texas study
revealed that plasma miR-141 was a sensitive marker and
complemented CEA for detecting Stage IV colon cancer. This
result was independently validated using a cohort of samples from
colon cancer patients in Tianjin, China. Thus, this collaborative
investigation carried out by two independent teams of researchers
at two different sites on different ethnic patient populations
provides strong evidence that miR-141 is a valid plasma marker
that complements CEA in determining stage IV colon cancer.
Importantly, our data also demonstrated that higher plasma miR-
141 was associated with shorter survival in both cohorts and that
miR-141 was an independent prognostic indicator for colon
cancer. We believe that the identification of miR-141 may
represent a key advancement in the search for valuable plasma
markers for colon cancer that have the potential to be translated
into clinical applications including prognosis, monitoring response
to therapy, and detecting disease recurrence. Further validation in
a larger cohort of samples and a prospective study will be needed
to determine conclusively whether miR-141 serves as a circulating
marker for late stage colon cancer.
Apart from the potential impact on clinical diagnosis and
prognosis, this study also revealed some intriguing aspects
regarding the origin of serum miRNAs in cancer. Results from
Figure 3. Combination of CEA and miR-141 identifies additional Stage IV cases in the training cohort. Two-parameter (expression of
miR-141 and CEA in plasma) classification is used to discriminate distant metastatic colon cancer. The cut-off value for CEA is 5.0 ng/mL, and for miR-
141 is 16.77 defined from the ROC curve. The corresponding cut-off values are marked by grey lines.
doi:10.1371/journal.pone.0017745.g003
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metastatic prostate cancer [12] link miR-141 to metastasis, we thus
tested a straightforward hypothesis that the elevated plasma miR-
141 reflected the elevated miR-141 level in tissue in Stage IV colon
cancer patients. However surprisingly, we did not observe a
significant difference in the miR-141 expression levels between
tumor tissues and adjacent normal tissues among different stages of
CRC or in tumor tissues between non-metastatic Stage I–II and
metastatic Stage IV. Therefore, the elevation of miR-141 in
plasma is not a simple indication of elevated miR-141 in
corresponding tumor tissues at the primary site. It is possible that
miR-141 is only elevated in the metastases at the secondary site.
MiR-141 belongs to the miR-200 family, which promotes the
mesenchymal-to-epithelial transition (MET) by inhibiting the
expression of the E-cadherin transcriptional suppressors ZEB1
and ZEB2 [15,16]. Thus it is consistent that we did not observe
elevated miR-141 at the primary site of Stage IV colon cancer
where EMT instead of MET is believed to occur resulting in cells
with higher potential for cell migration and metastasis. When
mesenchymal-like metastatic cells extravosate at distant site, a
transition to epithelial (MET) occurs, which may explain the surge
of miR-141 in metastatic cancer. This hypothesis will need to be
tested with matching primary tumors and metastases in the future.
Another possibility is that selected cellular miRNAs contribute
more significantly to the circulating miRNAs in cancer patients.
The in vitro studies also showed that miRNA expression profiles in
conditioned medium were different from those in cells, and those
secreted miRNAs may represent a class of signaling molecules in
mediating intercellular communication [17], although the mech-
anisms control microRNA packaging and secretion are largely
unknown. In cancer patients especially at late stage, there are
many systemic changes including inflammatory response that can
involve immune systems and other organs. It is conceivable that
these systemic responses may be a source of change in circulating
miRNAs in cancer patients. Along this line, in addition to colon
and prostate cancers, circulating miR-141 level has also been
associated with other pathophysiological conditions including
ovarian cancer [18] and pregnancy [19]. The difference in miR-
Figure 4. Higher plasma miR-141 level is associated with Stage IV colon cancer patients in the validation data set. Small RNA isolation
and miR-141 quantitative RT-PCR assays were performed in the same way as for the training cohort. (A) The Wilcoxon two-sample test was performed
to compare miR-141 levels between normal controls and/or colon cancer patients with different clinical stages. (B–D) The same analyses were
performed to compare miR-141 levels between Stage IV cases and Stage I–II cases (B), between Stage IV and Stage III cases (C), and between Stage IV
and Stage I–III cases (D), respectively. ROC analysis was performed to determine the sensitivity and specificity with the value of AUC in the right panel.
(E) Combination of CEA and miR-141 identified additional metastatic patients that were missed by either marker alone. See Figure 3 for the definition
of the cut-off values for CEA and miR-141.
doi:10.1371/journal.pone.0017745.g004
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related to differential inflammatory response in CRC and this
possibility will need to be further investigated in the future.
Among our candidate miRNAs, miR-21 is an oncogene that is
altered in many tumors by regulating the expression of multiple
cancer-related target genes such as PTEN and TPM1 [20,21].
Previous studies showed that expression of miR-21 was
upregulated in CRC tumor tissues and was gradually elevated
during tumor progression from early stage to late stage as
compared with matched non-tumor tissues, suggesting that it
would be a good circulating marker for CRC detection if this
same elevation trend were seen in plasma. However, our analysis
did not reveal a difference of plasma miR-21 between cancer
patients and healthy controls. Although circulating miR-21 was
also significantly elevated in patients with distant metastasis, the
sensitivity and specificity were much lower than those for miR-
141. Similarly, miR-92, a previously identified plasma markers
for CRC in the Hong Kong cohorts did not represent a useful
marker in our initial analysis of the TexGen cohort. We reason
that the genetic variations among different ethic groups as well as
environmental factors and diets may contribute to these
conflicting conclusions.
Table 1. Plasma miR-141 is an independent prognostic factor by Cox regression analysis.
Univariate analysis Multivariate analysis
Hazard ratio (95% CI) P1 Hazard ratio (95% CI) P2
TexGen
miR-141 3.80(1.46, 9.91) 0.006 1.36(0.45, 4.14) 0.589
Sex 0.43(0.20, 0.97) 0.042 0.45(0.19, 1.05) 0.063
Age 1.40(0.97, 1.12) 0.280 1.03(0.97, 1.10) 0.364
Stage 3.56(1.79, 7.09) 3.07610
24 3.37(1.50, 7.55) 0.003
Tianjin
miR-141 4.83(2.06, 11.35) 2.98610
24 3.41(1.36, 8.56) 0.009
Sex 1.47(0.63, 3.41) 0.370 1.02(0.43, 2.44) 0.964
Age 0.99(0.96, 1.03) 0.710 0.99(0.97, 1.03) 0.578
Stage 3.82(2.11, 6.93) 1.05610
25 3.22(1.75, 5.92) 1.67610
24
All Cases
miR-141 3.61(1.96, 6.65) 3.80610
25 2.40(1.18, 4.86) 0.016
*
Sex 0.75(0.42, 1.35) 0.337 0.65(0.36, 1.19) 0.162
*
Age 1.00(0.97, 1.04) 0.828 1.00(0.97, 1.03) 0.912
*
Stage 3.30(2.14, 5.09) 6.55610
28 3.16(1.97, 5.07) 1.90610
26*
*Adjusted by the different centers.
doi:10.1371/journal.pone.0017745.t001
Figure 5. MiR-141 in tumor tissues is not associated with colon cancer tumor stage. (A) Total RNA was isolated from tumor tissues of
metastatic or non-metastatic patients from the Tianjin cohort, and the miR-141 levels were measured with quantitative RT-PCR using RNU6B as an
endogenous control. The Wilcoxon two-sample test was performed to compare miR-141 expression in tumor tissues between these two groups. A
P,0.05 is considered significant. (B) The miR-141 expression levels were measured using microRNA profiling data from the Maryland cohort of CRC
samples. The Wilcoxon matched-pairs tests were performed to compare the miR-141 levels between tumor tissues and adjacent normal tissues in
these CRC patients.
doi:10.1371/journal.pone.0017745.g005
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our work suggested that the ongoing search for plasma miRNA
markers can be a fruitful process. In comparison to other
nucleotide molecules such as DNA and mRNA, miRNAs are
resistant to DNase or RNase activity and, thus, are relatively stable
in the circulation. In addition to our report here, there are
increasing examples of plasma miRNAs as potential biomarkers.
In acute leukemia patients, the plasma miR-92 level is dramat-
ically reduced (similar to what we observed with our CRC in this
study), and the ratio of miR-92a/miR-638 in plasma is a potential
biomarker for this disease [22]. In addition, plasma levels of a
panel of four miRNAs (miR-21, miR-210, miR-155, and miR-
196a) were found to be potential markers for pancreatic cancer
[23], and miR-31 upregulation in plasma may be a biomarker for
oral cancer [24]. These studies showed the potential of using
circulating miRNAs as biomarkers, but they are of limited value at
present because of a lack of independent validations. In our study,
the fact that plasma miR-141 was shown to be a prognostic factor
in two independent cohorts consisting of two different ethnic
populations provides compelling evidence that miR-141 may
emerges as a valuable marker of clinical significance.
Although biomarkers for advanced cancer can be potentially
used to monitor and predict therapeutic outcome, biomarkers that
can detect early stage disease and monitor early metastasis are
expected to represent more clinically relevant endpoints in the
increase of overall survival rate. Future efforts are still needed to
identify circulating microRNAs as biomarkers that can accurately
detect CRC at its early stage.
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Figure S1 Higher miR-141 predicts poor prognosis in
both cohorts. Kaplan-Meier survival curves for colon cancer
patients in both cohorts. The survival data were compared using
the log-rank test and miR-141 expression levels in patients defined
as high or low relative to the median. P-value of log-rank test is
0.004 and 0.002 in TexGen (A) and Tianjin (B) cohorts,
respectively. Higher plasma levels of miR-141 were associated
with poor overall survival in colon cancer patients.
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